Biotechnology Market Report (PPHM, AMGN, BIIB, GSK)
Peregrine Pharmaceuticals, Inc. ( NASDAQ
PHM ) recently announced financial results for the 1st quarter ended July 31, 2012 of fiscal year (FY) 2013 and provided an update on its advancing clinical pipeline and other corporate developments. Total revenues for the 1st quarter of FY 2013 were $4,251,000, compared to $5,655,000 for the same quarter of the prior fiscal year.
Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in the development and research of monoclonal antibodies for the treatment and diagnosis of cancer and viral infections.
Amgen (NASDAQ:AMGN) is set to present at the Morgan Stanley Global Healthcare Conference on Wednesday, Sept. 12, 2012 at the Grand Hyatt in New York City, starting at 2:10 p.m. Eastern Daylight Time. Jonathan M. Peacock, executive vice president and CFO at Amgen, will present.
As a biotechnology medicines company, Amgen Inc. develops, manufactures, discovers, and markets human therapeutics based on advances in cellular and molecular biology for grievous illnesses primarily in the United States, Europe, and Canada.
Biogen Idec (NASDAQ:BIIB) and DRI Capital announced today that Biogen Idec has sold to a DRI Capital managed fund its royalty and other rights relating to BENLYSTA to which Biogen Idec is entitled pursuant to a license agreement with Human Genome Sciences, Inc. and Glaxo Group Limited (both are companies are part of the GlaxoSmithKline group) (NYSE:GSK).
Biogen Idec Inc. develops, manufactures, discovers, and markets therapies for the treatment of hemophilia, neurodegenerative diseases, and autoimmune disorders in the United States and worldwide.
(0)
(0)NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
